Design of a peptide-based vaccine against human respiratory syncytial virus using a reverse vaccinology approach: evaluation of immunogenicity, antigenicity, allergenicity, and toxicity
BackgroundAttempts to develop an hRSV vaccine have faced safety and efficacy challenges, with only three FDA-approved vaccines (Moderna’s Mresvia, Pfizer’s Abrysvo, and GSK’s Arexvy) available. These vaccines are limited to individuals over 60 years, require boosters, and only reduce disease severit...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2025-03-01
|
| Serier: | Frontiers in Immunology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1546254/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
